Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Remands CRISPR …

Patent Law Expert neutral. Federal Circuit’s remand of CRISPR patent dispute creates uncertainty for Editas’ Cas9 patent portfolio but doesn’t …